Advertisement
Screener

Relay Therapeutics, Inc. (RLAY) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Relay Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Relay Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -32.14%, a change of 14.66% year-over-year.
  • Relay Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -42.47%, a change of 3.92% year-over-year.
  • Relay Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -48.76%, a change of -5.21% year-over-year.
  • Relay Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -48.97%, a change of -7.71% year-over-year.
  • Relay Therapeutics, Inc. return tang equity for fiscal 2025 was -48.76%, a change of -5.21% from fiscal 2024.
  • Relay Therapeutics, Inc. return tang equity for fiscal 2024 was -43.55%, a change of 2.07% from fiscal 2023.
  • Relay Therapeutics, Inc. return tang equity for fiscal 2023 was -45.61%, a change of -14.97% from fiscal 2022.
  • Relay Therapeutics, Inc. return tang equity for fiscal 2022 was -30.65%, a change of 9.99% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-32.14%-$286.04M$890.01M
2026-03-31-42.47%-$272.71M$642.18M
2025-12-31-48.76%-$276.48M$567.06M
2025-09-30-48.97%-$297.59M$607.71M
2025-06-30-46.80%-$311.55M$665.66M
2025-03-31-46.38%-$333.39M$718.78M
2024-12-31-43.55%-$337.71M$775.49M
2024-09-30-41.26%-$345.2M$836.56M
2024-06-30-47.51%-$322.83M$679.44M
2024-03-31-44.27%-$329.12M$743.46M
2023-12-31-45.61%-$341.97M$749.7M
2023-09-30-42.00%-$325.98M$776.07M
2023-06-30-42.64%-$344.42M$807.82M
2023-03-31-36.62%-$322.7M$881.11M
2022-12-31-30.65%-$290.51M$947.92M
2022-09-30-29.12%-$290.46M$997.47M
2022-06-30-34.36%-$267.12M$777.34M
2022-03-31-45.70%-$383.73M$839.67M
2021-12-31-40.63%-$363.87M$895.51M
2021-09-30-45.91%-$261.14M$568.79M
2021-06-30-38.36%-$236.39M$616.23M
2021-03-31-9.51%-$69.71M$732.79M
2020-12-31-6.87%-$52.41M$763.29M
2020-09-30-15.64%-$111.6M$713.53M
2020-06-3042.24%-$95.2M-$225.39M
2020-03-3142.50%-$86.01M-$202.35M
2019-12-3141.73%-$75.31M-$180.44M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-48.76%-$276.48M$567.06M
2024-12-31-43.55%-$337.71M$775.49M
2023-12-31-45.61%-$341.97M$749.7M
2022-12-31-30.65%-$290.51M$947.92M
2021-12-31-40.63%-$363.87M$895.51M
2020-12-31-6.87%-$52.41M$763.29M
2019-12-3141.73%-$75.31M-$180.44M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12